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A B S T R A C T
Background
Humidified high flow nasal cannula (HHFNC) delivers humidified gas at increased flow rates via binasal prongs and is becoming
widely accepted as a method of non-invasive respiratory support for preterm infants. While indications for the use of (HHFNC) and
its associated risks and benefits are being investigated, the best strategy for the discontinuation of HHFNC remains unknown. At what
point an infant is considered stable enough to attempt to start withdrawing their HHFNC is not known. The criteria for a failed
attempt at HHFNC discontinuation is also unclear.
Objectives
To determine the risks and benefits of different strategies used for the discontinuation of HHFNC in preterm infants.
Search methods
We searched the Cochrane Neonatal Review Group Specialized Register, PubMed (1966 to March 2015), CINAHL (1982 to March
2015), EMBASE (1980 to March 2015), and the Cochrane Central Register of Controlled Trials (CENTRAL). Also, we checked
previous reviews, including cross references. We searched for following web sites for ongoing trials: ClinicalTrials.gov and controlled-
trials.com.
Selection criteria
We included randomised controlled trials (RCTs) and quasi-RCTs in which either individual newborn infants or clusters of infants (such
as separate neonatal units) were randomised to different HHFNC withdrawal strategies (from the first time they come off HHFNC
and any subsequent weaning, or withdrawal attempt, or both).
Data collection and analysis
We used standard methods of Cochrane and the Cochrane Neonatal Review Group.
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Main results
We identified no eligible studies examining the best strategy to wean or withdraw HHFNC once started as respiratory support in
preterm infants
Authors’ conclusions
There is currently no evidence available to suggest the best strategy for weaning and withdrawing HHFNC as a respiratory support
in preterm infants. Research is required into the best strategy for withdrawal of HHFNC and to which subgroups this applies. Clear
criteria for the definition of stability prior to attempting to withdraw HHFNC needs to be established. Furthermore, clear definitions
are needed as to what constitutes failure of HHFNC.
P L A I N L A N G U A G E S U M M A R Y
Strategies used for the withdrawal of humidified high flow nasal cannulae (HHFNC) in preterm infants
Background:Humidified high flow nasal cannula (HHFNC) is a form of respiratory support used in the treatment of preterm infants.
Potential risks of HHFNC include damage to the nose and leaking of air from the lungs. Infants on HHFNC require more nursing care
and the use of extra equipment (when compared to not being on any support). However, potential complications of removing HHFNC
from babies too early include increased episodes of forgetting to breathe, increased oxygen needs, increased effort of breathing, the
need to restart HHFNC, and the need for a breathing tube with mechanical ventilation. Any of these complications can be seen as a
“failure” and are potentially distressing to staff and family. The best way to withdraw HHFNC once it has been started is unknown.
Options include simply stopping, weaning the flow, increasing the time off HHFNC each day, or combinations of both.
Study question :What are the benefits and risks of different strategies used for the withdrawal of HHFNC in preterm infants who are
stable and may be ready to have HHFNC withdrawn?
Study characteristics and key findings:Researchers from Cochrane searched for all available literature up to 30 March 2015. We
did not identify any eligible studies looking at the best strategy to wean or withdraw HHFNC once started as respiratory support in
preterm infants for inclusion in this Cochrane review.
Conclusions: The best strategy for weaning, or withdrawal, or both, of HHFNC used as a form of respiratory support in preterm
infants remains unclear. Studies are required to answer these questions. Clear criteria are needed to establish a definition of stability
prior to attempting to withdraw HHFNC, and for failure to withdraw/wean HHFNC.
B A C K G R O U N D
Description of the condition
Humidified high flow nasal cannula (HHFNC) delivers humidi-
fied gas at increased flow rates via binasal prongs. The definition
of ’high flow’ varies; in a recent Cochrane review, Wilkinson 2011
defined high flow as greater than 1 L/min, whereas others have
suggested that HHFNC is when flow rates are greater than 2 L/
min (Manley 2012a). HHFNC is becoming widely accepted as
a method of non-invasive respiratory support within neonatal in-
tensive care nurseries and non-tertiary nurseries (Holleman-Duray
2007; Shoemaker 2007; Hochwald 2010; Nath 2010; Hough
2012;Manley 2012b). Clinical situations inwhichHHFNC is be-
ing used include primary respiratory therapy for infants with res-
piratory distress syndrome (RDS), apnoea of prematurity (AOP),
prevention of extubation failure, and weaning from nasal con-
tinuous positive airway pressure (NCPAP) (Abdel-Hady 2011;
Iranpour 2011; Manley 2012a). This comes despite ongoing con-
cerns over both its safety and efficacy in the neonatal popula-
tion, with a Cochrane review examining the risks and benefits
(Wilkinson 2011) of HHFNC concluding that insufficient evi-
dence exists to determine its use as a form of respiratory support
in preterm infants.
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Description of the intervention
While continued investigations are attempting to determine both
the optimal technique of HHFNC delivery and the clinical setting
in which it is most useful, the best strategy for the stopping or
weaning of HHFNC remains unknown. At what point an infant
is considered stable enough to attempt to start withdrawing their
HHFNC is not clearly established. The criteria for a failed at-
tempt at HHFNC withdrawal are unclear. A recent study looked
at possible methods for weaning NCPAP in preterm infants (Todd
2012). Clearly defined criteria for stability prior to weaning, and
for failing once off CPAP, were given. Whether these criteria are
applicable to HHFNC is unknown, and requires investigation.
Possible strategies for the withdrawal of HHFNC include:
1. Stopping HHFNC completely, independent of the level of
air flow, and remaining off HHFNC unless certain criteria are
met that require the infant to go back onto HHFNC;
2. Decreasing HHFNC to a predefined flow, then stopping
HHFNC completely;
3. Removing HHFNC for a predetermined number of hours
each day (this can be a single time period: e.g. 4 hours off, 20
hours on; or a number of smaller time periods e.g. one hour off,
five hours on), gradually increasing the amount of time off
HHFNC each day until HHFNC is able to be stopped
completely (graded time off );
4. Stopping HHFNC and starting low flow oxygen via a nasal
cannula;
5. Combinations of the above strategies (e.g. decreasing
HHFNC to a defined flow and then discontinuing HHFNC for
a number of hours each day);
6. Combinations of the above strategies in addition to co-
interventions (e.g. methylxanthines).
How the intervention might work
The possible benefits of differentmethods ofHHFNCwithdrawal
are unknown. Weaning the flow rate may gradually increase res-
piratory muscle strength without the associated risk of atelectasis.
Having periods of time off may have a similar effect of respira-
tory muscle training, but for shorter, more intense periods. Time
off HHFNC may be more likely to cause ’atelectotrauma’ (due
to alveolar collapse when off HHFNC and re-recruitment once
HHFNC recommences). Having periods of time off HHFNC
may reduce the risk of developing adverse effects, given reports
that its use may lead to mucosal irritation, nasal bleeding, and
obstruction (Kopelman 2003). An appropriate weaning strategy
may alleviate any concerns of lung overdistension from unmea-
sured positive end-expiratory pressure (PEEP) (Finer 2009), and
any other possible risks (Wilkinson 2011).
Why it is important to do this review
HHFNC is being used in increasing frequency in neonatal units,
despite ongoing concerns over its safety and efficacy.While a num-
ber of trials are underway to determine the best role for HHFNC
in respiratory support of neonates, there are a number of reported
strategies as to how to ceaseHHFNConce it has been commenced.
It is unknown as to the best strategy for withdrawal and to what
patient groups this should apply. This review complements the
Cochrane review on “Strategies for the withdrawal of nasal contin-
uous positive airway pressure in preterm infants” (Jardine 2011).
O B J E C T I V E S
To determine the benefits and harms of different strategies for the
withdrawal of HHFNC in preterm infants who are stable and may
be ready to have HHFNC withdrawn.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We considered all eligible randomised controlled trials (RCTs) and
quasi-RCTs in which either individual newborn infants or clusters
of infants (such as separate neonatal units) were randomised to
different HHFNC withdrawal strategies (from the first time they
come off HHFNC and any subsequent weaning, or withdrawal
attempt, or both).
Types of participants
Spontaneously breathing preterm infants (< 37 weeks com-
pleted gestational age) currently receiving respiratory support via
HHFNCfor any indication,who remain inpatients, and forwhom
the decision had been made to attempt discontinuation/with-
drawal of respiratory support. We excluded infants in whom the
decision to discontinue respiratory support was taken as part of
withdrawing life-sustaining therapy. Participants should have met
criteria for stability (however defined in individual studies) prior
to their first attempt at withdrawal. We planned to exclude trials
that did not include criteria for stability.
Types of interventions
Any strategy that involved the stopping or gradual withdrawal of
HHFNC (> 1 L/minute). Strategies include:
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1. Stopping HHFNC completely, independent of the level of
air flow, and remaining off HHFNC unless certain criteria are
met that require the infant to go back onto HHFNC;
2. Decreasing HHFNC to a predefined flow, then stopping
HHFNC completely;
3. Removing HHFNC for a predetermined number of hours
each day (this can be a single time period: e.g. 4 hours off, 20
hours on; or a number of smaller time periods e.g. one hour off,
five hours on), gradually increasing the amount of time off
HHFNC each day until HHFNC is able to be stopped
completely (graded time off );
4. Stopping HHFNC and starting low flow air (and oxygen if
required) via a nasal cannula;
5. Combinations of the above strategies (e.g. decreasing
HHFNC to a defined flow and then discontinuing HHFNC for
a number of hours each day);
6. Combinations of the above strategies in addition to co-
interventions (e.g. methylxanthines).
Types of outcome measures
We planned intention-to-treat (ITT) analysis based on the first
assigned method of withdrawal.
Primary outcomes
• Time (from treatment group allocation) to successfully
remaining off HHFNC altogether (hours, days);
• Failure to wean off HHFNC (e.g. needing to restart
HHFNC once it has stopped, or needing to restart HHFNC
during time off HHFNC, or delaying any further weaning off
HHFNC, or needing to commence/return to NCPAP or
ventilation), however defined in individual studies.
Secondary outcomes
• Duration of HHFNC from initial intervention (days);
• Total duration of all respiratory support (i.e. any form of
mechanical ventilation or NCPAP or HHFNC);
• Duration of hospital stay (days);
• Endotracheal intubation and mechanical ventilation,
excluding episodes required for elective procedures (e.g. surgery);
• Incidence of air leak (any, and those requiring drainage)
from time of treatment group allocation;
• Apnoea (defined as cessation of breathing > 20 seconds or >
10 seconds with desaturation, or however defined in individual
studies);
• Nasal trauma including nasal bleeding;
• Duration of oxygen therapy (days);
• Chronic lung disease (oxygen requirement at 36 weeks
postmenstrual age);
• Mortality (< 28 days);
• Mortality (at hospital discharge);
• Mortality (at one year);
• Long-term major neurodevelopmental disability (CP,
developmental delay (Bayley or Griffith assessment more than
two standard deviations (SD) below the mean) or intellectual
impairment (intelligence quotient (IQ) more than two SD below
mean), blindness (vision < 6/60 in both eyes), sensorineural
deafness requiring amplification). We planned to report long-
term outcomes for all studies that evaluated children after 18
months’ chronological age. We planned to perform separate
analyses for children aged 18 to 24 months and over three years;
• Any other clinically-relevant outcomes identified in
individual studies.
Search methods for identification of studies
Electronic searches
We used the standard search strategy for the Cochrane Neona-
tal Review Group. We searched the Cochrane Neonatal Review
Group Specialised Register, CENTRAL (2015, Issue 3), PubMed
(1966 to March 2015), EMBASE (1980 to March 2015), and
CINAHL (1982 to March 2015), using the following strategy:
The text words “humidified high flow nasal cannula”, “humidified
high flow nasal cannulae”, “humidified high-flow nasal cannulae”,
“high flow nasal cannula”, “high-flow nasal cannula
AND
MeSH search term ”Infant, Premature“ OR the text words
”neonat$“, ”infant“, ”preterm“, ”newborn“, ”premature“.
AND
MeSHsearch term”VentilatorWeaning“OR textwords ”ceasing“,
”cessation“, ”wean“, ”weaning“, ”stop“, ”stopping“, ”withdraw$“,
”discontin$“, ”taper$“.
We did not restrict searches to publications in the English lan-
guage.
Searching other resources
We searched previous reviews (including cross references) without
restricting searches to publications in the English language or to
published data. In addition, we checked the following websites for
ongoing trials: clinicaltrials.gov and controlled-trials.com.
We searched for abstracts from the Pediatric Academic Societies’
Annual Meeting (Abstract2view) online 2000 to 2014.
Data collection and analysis
We planned to use the standard methods of Cochrane and the
Cochrane Neonatal Review Group. We analysed only studies that
allocated subsequent withdrawal attempts to the policy originally
allocated.
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Selection of studies
Two review authors independently screened trials for inclusion.
Data extraction and management
Review authors extracted data independently and resolved differ-
ences by discussion. We planned to contact study investigators for
additional information or data as required. Also we planned to
collect predefined outcome measures with the aid of a data collec-
tion form.
Assessment of risk of bias in included studies
Two review authors planned to independently assess trials for
methodological quality. We planned to evaluate the following is-
sues and enter the findings into the ’Risk of bias’ tables (Higgins
2011):
1. Sequence generation (checking for possible selection bias):
For each included study, we planned to categorise the method
used to generate the allocation sequence as:
i) Low risk (any truly random process e.g. random
number table; computer random number generator);
ii) High risk (any non random process e.g. odd or even
date of birth; hospital or clinic record number);
iii) Unclear risk.
2. Allocation concealment (checking for possible selection
bias): For each included study, we planned to categorise the
method used to conceal the allocation sequence as:
i) Low risk (e.g. telephone or central randomisation;
consecutively numbered sealed opaque envelopes);
ii) High risk (open random allocation; unsealed or non-
opaque envelopes; alternation; date of birth);
iii) Unclear risk.
3. Blinding (checking for possible performance bias): For each
included study, we planned to categorise the methods used to
blind study participants and personnel from knowledge of which
intervention a participant received. We planned to categorise
blinding separately for different outcomes or classes of outcomes.
We planned to categorise the methods as:
i) Low risk, high risk, or unclear risk for participants;
ii) Low risk, high risk, or unclear risk for personnel;
iii) Low risk, high risk, or unclear risk for outcome
assessors.
4. Incomplete outcome data (checking for possible attrition
bias through withdrawals, dropouts, protocol deviations): For
each included study and for each outcome, we planned to
describe the completeness of data including attrition and
exclusions from the analysis. We planned to note whether
attrition and exclusions were reported, the numbers included in
the analysis at each stage (compared with the total randomised
participants), reasons for attrition or exclusion where reported,
and whether missing data were balanced across groups or were
related to outcomes. Where sufficient information was reported
or supplied by the trial authors, we planned to re-include missing
data in the analyses. We planned to categorise the methods as:
i) Low risk (< 20% missing data);
ii) High risk (≥ 20% missing data);
iii) Unclear risk.
5. Selective reporting bias: For each included study, we
planned to describe how we investigated the possibility of
selective outcome reporting bias and what we found. We
planned to assess the methods as:
i) Low risk (where it is clear that all of the study’s pre-
specified outcomes and all expected outcomes of interest to the
review have been reported);
ii) High risk (where not all the study’s pre-specified
outcomes have been reported; one or more reported primary
outcomes were not pre-specified; outcomes of interest are
reported incompletely and so cannot be used; study fails to
include results of a key outcome that would have been expected
to have been reported);
iii) Unclear risk.
6. Other sources of bias: For each included study, we planned
to describe any important concerns we had about other possible
sources of bias (e.g. whether there was a potential source of bias
related to the specific study design or whether the trial was
stopped early due to some data-dependent process). We planned
to assess whether each study was free of other problems that
could put it at risk of bias as:
i) Low risk;
ii) High risk;
iii) Unclear risk.
Measures of treatment effect
We planned to perform statistical analyses using RevMan 2014
software. We planned to analyse categorical data using relative
risk (RR), absolute risk difference (RD) and number needed to
treat for an additional beneficial outcome (NNTB) or the number
needed to treat for an additional harmful outcome (NNTH). We
planned to analyse continuous data using mean difference (MD)
and report the 95% confidence interval (CI) on all estimates.
Unit of analysis issues
We planned to include cluster-RCTs in this Cochrane review and
to confirm that the order of treatments had been randomised
(Higgins 2002). We planned to attempt to access paired and un-
paired data (Higgins 2002) and to impute the correlation coef-
ficient from data provided in the included studies in this meta-
analysis. If this was not available, we planned to assume a value of
0.4 and conduct a sensitivity analysis by successively using r = 0.3
and 0.5.
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Dealing with missing data
We planned to attempt to contact trial authors for missing data.
We planned to perform an ITT analysis based on the assigned
method of withdrawal.
Assessment of heterogeneity
If a sufficient number of studies met the inclusion criteria, we
planned to assess heterogeneity using the I2 statistic and the fol-
lowing cutoffs: < 25% no heterogeneity; 25% to 49% low hetero-
geneity; 50% to 74% moderate heterogeneity; and ≥ 75% high
heterogeneity. If we identified statistical heterogeneity, we planned
to look for an explanation for this heterogeneity.
Assessment of reporting biases
In order to determine if there might be selective reporting, we
planned to look for pre-specified outcomes in trial registries and
compare these to reported outcomes. If there were discrepancies,
we planned to attempt to contact the corresponding trial author.
In examining for duplication bias, we closely examined articles
from repeated authors or sites and compare sample size, charac-
teristics, and details of studies. If there appeared to be overlap, we
planned to attempt to contact the corresponding trial author.
If we were not successful in contacting authors, we planned to
included the possible sources of reporting bias in our conclusions.
To test for publication bias, we planned to perform a forest plot if
there were ≥ 10 studies included in a meta-analysis.
We planned to examine the range of languages, location, and ci-
tation sources to examine potential bias.
Data synthesis
For the meta-analysis we planned to report MD and 95% CI for
continuous variables. For the categorical outcomes we planned
to report the RR, RD, and 95% CIs. When RD was statistically
significant, NNTB and NNTH were planned to be examined.
We planned to use the fixed-effect model for meta-analysis.
Subgroup analysis and investigation of heterogeneity
We planned to conduct subgroup analyses in an attempt to deter-
mine whether results differed by:
1. Gestational age at birth (e.g. < 29 weeks, ≥ 29 weeks);
2. Birth weight (e.g. < 1000 gm, ≥ 1000 gm);
3. Postnatal age (e.g. < four weeks of age, ≥ four weeks of age);
4. Indication for HHFNC (e.g. respiratory distress, post
extubation, apnoea, chronic lung disease);
5. Delivery method of HHFNC (e.g. single prong versus
binasal prong, bubble bottles versus ventilator);
6. Delivery device of HHFNC (e.g. Vapotherm or Fisher &
Paykel).
Sensitivity analysis
We planned to perform a sensitivity analysis (data permitting)
to see if results differed by the quality of included studies (e.g.
adequacy of randomisation: quasi-RCT versus RCT).
R E S U L T S
Description of studies
Results of the search
Using the search strategy detailed above, we identified a num-
ber of studies for inclusion. However, after screening, no studies
were eligible for inclusion. None of the studies we found included
methods for weaningHHFNC, withmost looking at comparisons
between HHFNC and NCPAP.
Included studies
No studies met the inclusion criteria.
Excluded studies
None
Risk of bias in included studies
Not applicable.
Allocation
Not applicable.
Blinding
Not applicable.
Incomplete outcome data
Not applicable.
Selective reporting
Not applicable.
Other potential sources of bias
Not applicable.
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Effects of interventions
Not applicable.
D I S C U S S I O N
The evidence to support the use of HHFNC is evolving.
Wilkinson 2011 identified four studies for inclusion in aCochrane
review of high flow nasal cannula (HFNC). The studies differed
in the interventions compared (nasal CPAP, HHFNC, non-hu-
midified HFNC), the flow rates provided, and the indications for
respiratory support. Wilkinson 2011 concluded that there was in-
sufficient evidence to determine the risks and benefits of using
HHFNC as a form of respiratory support in preterm infants.
SinceWilkinson 2011, several larger trials of heatedHHFNChave
been reported. Yoder 2013 performed a randomised controlled
unblinded non-crossover trial in 432 infants ranging from 28 to
42 weeks’ gestational age with planned nasal CPAP support, as
either primary therapy or postextubation. There was no differ-
ence in early failure (HHFNC 10.8% vs. nasal CPAP 8.2%; P =
0.344), subsequent need for any intubation (HHHFNC 15.1%
vs. nasal CPAP 11.4%; P = 0.252), or in any of several adverse
outcomes analysed including days on supplemental oxygen, bron-
chopulmonary dysplasia, or discharge from the hospital on oxy-
gen.
Manley 2013 performed a multicentre, randomised, non-inferi-
ority trial comparing HHFNC (5 to 6 L/minute) or nasal CPAP
(7 cm H2O) after extubation in 303 infants studies. HHFNC use
was non-inferior to nasal CPAP use, with treatment failure occur-
ring in 34.2% of infants in the nasal-cannula group and 25.8%
of infants in the CPAP group (risk difference 8.4%, 95% CI -1.9
to 18.7%). The incidence of nasal trauma was significantly lower
in the nasal cannula group than in the CPAP group (P = 0.01),
but there were no significant differences in rates of serious adverse
events or other complications.
HHFNC has come into widespread use in neonatal intensive care
units, with over half of very low birthweight infants treated with
HHHFNC at some point in their intensive care stay (Soll 2013).
However, in our Cochrane review, we did not identify any studies
providing information on the bestmethod of weaningHHFNC in
preterm infants who are stable and may be ready to have HHFNC
withdrawn.
Research is required into the best methods for withdrawal of
HHFNCand towhich subgroups these apply. Clear criteria for the
definition of stability prior to attempting to withdraw HHFNC
needs to be established. Furthermore, clear definitions should be
established as to what constitutes failure of HHFNC. A recent
study (Todd 2012) looked at possible methods for weaning NC-
PAP in preterm infants. Clearly defined criteria for stability prior
to weaning, and for failing once off CPAP, were given. Whether
these criteria are applicable to HHFNC is unknown, and requires
investigation.
Summary of main results
Not applicable.
Overall completeness and applicability of
evidence
Not applicable.
Quality of the evidence
Not applicable.
Potential biases in the review process
Not applicable.
Agreements and disagreements with other
studies or reviews
Not applicable.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
There is no currently available evidence to suggest the best strategy
for weaning and withdrawing HHFNC as a respiratory support
in preterm infants.
Implications for research
Research is required into the best methods for withdrawal of
HHFNCand towhich subgroups these apply. Clear criteria for the
definition of stability prior to attempting to withdraw HHFNC
needs to be established. Furthermore, clear definitions should be
established as to what constitutes failure of HHFNC.
A C K N OW L E D G E M E N T S
None.
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D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
We added a more precise definition of ”long-term major neurodevelopmental disability“ (CP, developmental delay (Bayley or Griffith
assessment > two SDs below themean) or intellectual impairment (intelligence quotient (IQ) > two SDs belowmean), blindness (vision
< 6/60 in both eyes), sensorineural deafness requiring amplification). Long-term outcomes will be reported for all studies that have
evaluated children after 18 months’ chronological age. We will perform separate analyses for children aged 18 to 24 months and over
three years.
10Strategies for the discontinuation of humidified high flow nasal cannula (HHFNC) in preterm infants (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
